These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 8440926)

  • 1. A human respiratory syncytial virus (RSV) primate model of enhanced pulmonary pathology induced with a formalin-inactivated RSV vaccine but not a recombinant FG subunit vaccine.
    Kakuk TJ; Soike K; Brideau RJ; Zaya RM; Cole SL; Zhang JY; Roberts ED; Wells PA; Wathen MW
    J Infect Dis; 1993 Mar; 167(3):553-61. PubMed ID: 8440926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV.
    Connors M; Collins PL; Firestone CY; Sotnikov AV; Waitze A; Davis AR; Hung PP; Chanock RM; Murphy BR
    Vaccine; 1992; 10(7):475-84. PubMed ID: 1609551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease.
    Murphy BR; Sotnikov A; Paradiso PR; Hildreth SW; Jenson AB; Baggs RB; Lawrence L; Zubak JJ; Chanock RM; Beeler JA
    Vaccine; 1989 Dec; 7(6):533-40. PubMed ID: 2692334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced pulmonary pathology associated with the use of formalin-inactivated respiratory syncytial virus vaccine in cotton rats is not a unique viral phenomenon.
    Piedra PA; Wyde PR; Castleman WL; Ambrose MW; Jewell AM; Speelman DJ; Hildreth SW
    Vaccine; 1993 Nov; 11(14):1415-23. PubMed ID: 7508665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization.
    Murphy BR; Sotnikov AV; Lawrence LA; Banks SM; Prince GA
    Vaccine; 1990 Oct; 8(5):497-502. PubMed ID: 2251875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of respiratory syncytial virus (RSV) infected cells by in situ hybridization in the lungs of cotton rats immunized with formalin-inactivated virus or purified RSV F and G glycoprotein subunit vaccine and challenged with RSV.
    Murphy BR; Prince GA; Lawrence LA; Croen KD; Collins PL
    Virus Res; 1990 Jun; 16(2):153-62. PubMed ID: 2385958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination of cotton rats with a chimeric FG glycoprotein of human respiratory syncytial virus induces minimal pulmonary pathology on challenge.
    Wathen MW; Kakuk TJ; Brideau RJ; Hausknecht EC; Cole SL; Zaya RM
    J Infect Dis; 1991 Mar; 163(3):477-82. PubMed ID: 1995720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
    Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity.
    Murphy BR; Walsh EE
    J Clin Microbiol; 1988 Aug; 26(8):1595-7. PubMed ID: 2459154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Both immunisation with a formalin-inactivated respiratory syncytial virus (RSV) vaccine and a mock antigen vaccine induce severe lung pathology and a Th2 cytokine profile in RSV-challenged mice.
    Boelen A; Andeweg A; Kwakkel J; Lokhorst W; Bestebroer T; Dormans J; Kimman T
    Vaccine; 2000 Nov; 19(7-8):982-91. PubMed ID: 11115725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine.
    Murphy BR; Prince GA; Walsh EE; Kim HW; Parrott RH; Hemming VG; Rodriguez WJ; Chanock RM
    J Clin Microbiol; 1986 Aug; 24(2):197-202. PubMed ID: 3755730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate.
    Li X; Sambhara S; Li CX; Ettorre L; Switzer I; Cates G; James O; Parrington M; Oomen R; Du RP; Klein M
    Virology; 2000 Mar; 269(1):54-65. PubMed ID: 10725198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of detectable enhanced pulmonary histopathology in cotton rats immunized with purified F glycoprotein of respiratory syncytial virus (RSV) when challenged at 3-6 months after immunization.
    Hildreth SW; Baggs RR; Brownstein DG; Castleman WL; Paradiso PR
    Vaccine; 1993; 11(6):615-8. PubMed ID: 8322482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the ability of formalin-inactivated respiratory syncytial virus, immunopurified F, G and N proteins and cell lysate to enhance pulmonary changes in Balb/c mice.
    Vaux-Peretz F; Chapsal JM; Meignier B
    Vaccine; 1992; 10(2):113-8. PubMed ID: 1539464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells.
    Connors M; Kulkarni AB; Firestone CY; Holmes KL; Morse HC; Sotnikov AV; Murphy BR
    J Virol; 1992 Dec; 66(12):7444-51. PubMed ID: 1433525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unveiling Integrated Functional Pathways Leading to Enhanced Respiratory Disease Associated With Inactivated Respiratory Syncytial Viral Vaccine.
    Russell MS; Creskey M; Muralidharan A; Li C; Gao J; Chen W; Larocque L; Lavoie JR; Farnsworth A; Rosu-Myles M; Hashem AM; Yauk CL; Cao J; Van Domselaar G; Cyr T; Li X
    Front Immunol; 2019; 10():597. PubMed ID: 30984178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogen-induced enhanced pulmonary histopathology in the RSV cotton rat model.
    Hildreth SW; Baggs RR; Brownstein DG; Castleman WL; Paradiso PR
    Vaccine; 1993; 11(6):689-90. PubMed ID: 8322496
    [No Abstract]   [Full Text] [Related]  

  • 18. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis.
    Piedra PA; Grace S; Jewell A; Spinelli S; Bunting D; Hogerman DA; Malinoski F; Hiatt PW
    Pediatr Infect Dis J; 1996 Jan; 15(1):23-31. PubMed ID: 8684872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination with a heterologous respiratory syncytial virus chimeric FG glycoprotein demonstrates significant subgroup cross-reactivity.
    Oien NL; Brideau RJ; Thomsen DR; Homa FL; Wathen MW
    Vaccine; 1993; 11(10):1040-8. PubMed ID: 8212825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental animal model for analyzing immunobiological responses following vaccination with formalin-inactivated respiratory syncytial virus.
    Sawada A; Nakayama T
    Microbiol Immunol; 2016 Apr; 60(4):234-42. PubMed ID: 26865035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.